<?xml version="1.0" encoding="UTF-8" ?> 

<rss version="2.0"> 
<channel> 
<title>Breast News</title> 
<link>http://www.mdlinx.com/HemeOncLinx/news.cfm/newspage/1/spec_id/17/subspec_id/387</link> 
<description>Breast</description> 
<language>en-us</language> 
<copyright>Copyright 2009 MDLinx, Inc.</copyright>










 



<item> 
<title><![CDATA[Bevacizumab in the treatment of breast cancer]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2960972</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Cancer Treatment Reviews</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2960972</guid>
</item> 
 

<item> 
<title><![CDATA[Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959323</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Cancer</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959323</guid>
</item> 
 

<item> 
<title><![CDATA[Gene promoter methylation is associated with increased mortality among women with breast cancer]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959844</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Breast Cancer Research and Treatment</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959844</guid>
</item> 
 

<item> 
<title><![CDATA[Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959840</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Breast Cancer Research and Treatment</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959840</guid>
</item> 
 

<item> 
<title><![CDATA[Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959842</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Breast Cancer Research and Treatment</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959842</guid>
</item> 


 

<item> 
<title><![CDATA[Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959845</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Breast Cancer Research and Treatment</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959845</guid>
</item> 
 

<item> 
<title><![CDATA[A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959843</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Breast Cancer Research and Treatment</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959843</guid>
</item> 
 

<item> 
<title><![CDATA[Association of rare MSH6 variants with familial breast cancer]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959841</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Breast Cancer Research and Treatment</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959841</guid>
</item> 
 

<item> 
<title><![CDATA[Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2962788</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Molecular and Cellular Endocrinology</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2962788</guid>
</item> 
 

<item> 
<title><![CDATA[Identification of novel ER-alpha target genes in breast cancer cells: Gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2962816</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Molecular and Cellular Endocrinology</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2962816</guid>
</item> 
 
 


  


</channel> 
</rss>

